NJ BIO INC
The Senior Director, Business Development will drive commercial growth initiatives for CRDMO service offerings, focusing on antibody-drug conjugates (ADCs) and related modalities. This role involves identifying new customer relationships, expanding existing accounts, and representing the organization in the Greater Boston Region. The position requires developing strategic partnerships and translating market opportunities into sustainable business scaling.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for NJ BIO INC.
Scientist I/II
MacroGenics
Scientist III, Bioconjugation (ADC) Process Development
Exelixis
Advisor ADC Drug-Linker Synthetic Process Development
Eli Lilly and Company
Director, Antibody Drug Conjugate
Exelixis
Scientist III - Bioconjugation (ADC) Process Development
Exelixis
Principal Scientist, ADC and Bioconjugation
Gilead Sciences